Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of intravenous Contezolid Acefosamil followed by oral contezolid versus linezolid in adults with moderate or severe diabetic foot infection
CTR20221821Phase 3Active
- Sponsor
- MicuRx Pharmaceuticals
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of contezolid acefosamil, contezolid, linezolid in diabetic foot infection (DFI), sponsored by MicuRx Pharmaceuticals. Started Jul 2022; status: active.
02
Drugs
contezolid acefosamilcontezolidlinezolid
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on CTR20221821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221821.